Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival

Katherine R. Birchard, Jenny K. Hoang, James E. Herndon, Edward F. Patz

Research output: Contribution to journalArticle

Abstract

BACKGROUND: In clinical trials, change in tumor size is used to stratify patients into response categories. The objective of the current study was to: 1) determine whether early change in the tumor size were correlated with survival in patients with advanced nonsmall cell lung cancer (NSCLC) using modified response categories from the Response Evaluation Criteria in Solid Tumors (RECIST), and 2) to determine whether there was an optimal percentage change in tumor size that could be used to define a partial response that also correlated with survival. METHODS: A total of 99 consecutive patients presenting for the treatment of advanced NSCLC during the year 2003 who had computed tomography (CT) scans before and after treatment available for review were included in the study. The largest target thoracic lesion was measured on CT before treatment, and again 2 months to 3 months after the initiation of treatment. Percent change in tumor size was calculated. The relation between tumor response and patient survival was investigated. RESULTS: There was no definite relation noted between early tumor response and patient survival (P = .754). Patients who had any initial reduction in tumor size were not found to have a significantly different survival compared with patients with initial disease progression (P = .580). In addition, there was no particular percent reduction in tumor size that was found to optimally correlate with survival. CONCLUSIONS: There is no evidence of a relation between early changes in tumor size and survival among patients with advanced stage NSCLC. To predict survival in patients with advanced NSCLC, response criteria other than change in lesion size are needed.

Original languageEnglish (US)
Pages (from-to)581-586
Number of pages6
JournalCancer
Volume115
Issue number3
DOIs
StatePublished - Feb 1 2009
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Survival
Neoplasms
Tomography
Therapeutics
Disease Progression
Thorax
Clinical Trials

Keywords

  • Change in lesion size
  • Computed tomography
  • Nonsmall cell lung cancer
  • RECIST
  • Survival
  • Tumor measurements
  • Tumor response

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. / Birchard, Katherine R.; Hoang, Jenny K.; Herndon, James E.; Patz, Edward F.

In: Cancer, Vol. 115, No. 3, 01.02.2009, p. 581-586.

Research output: Contribution to journalArticle

Birchard, Katherine R. ; Hoang, Jenny K. ; Herndon, James E. ; Patz, Edward F. / Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. In: Cancer. 2009 ; Vol. 115, No. 3. pp. 581-586.
@article{81400ac8b1af49e1a89e72ea1aefb67d,
title = "Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival",
abstract = "BACKGROUND: In clinical trials, change in tumor size is used to stratify patients into response categories. The objective of the current study was to: 1) determine whether early change in the tumor size were correlated with survival in patients with advanced nonsmall cell lung cancer (NSCLC) using modified response categories from the Response Evaluation Criteria in Solid Tumors (RECIST), and 2) to determine whether there was an optimal percentage change in tumor size that could be used to define a partial response that also correlated with survival. METHODS: A total of 99 consecutive patients presenting for the treatment of advanced NSCLC during the year 2003 who had computed tomography (CT) scans before and after treatment available for review were included in the study. The largest target thoracic lesion was measured on CT before treatment, and again 2 months to 3 months after the initiation of treatment. Percent change in tumor size was calculated. The relation between tumor response and patient survival was investigated. RESULTS: There was no definite relation noted between early tumor response and patient survival (P = .754). Patients who had any initial reduction in tumor size were not found to have a significantly different survival compared with patients with initial disease progression (P = .580). In addition, there was no particular percent reduction in tumor size that was found to optimally correlate with survival. CONCLUSIONS: There is no evidence of a relation between early changes in tumor size and survival among patients with advanced stage NSCLC. To predict survival in patients with advanced NSCLC, response criteria other than change in lesion size are needed.",
keywords = "Change in lesion size, Computed tomography, Nonsmall cell lung cancer, RECIST, Survival, Tumor measurements, Tumor response",
author = "Birchard, {Katherine R.} and Hoang, {Jenny K.} and Herndon, {James E.} and Patz, {Edward F.}",
year = "2009",
month = "2",
day = "1",
doi = "10.1002/cncr.24060",
language = "English (US)",
volume = "115",
pages = "581--586",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival

AU - Birchard, Katherine R.

AU - Hoang, Jenny K.

AU - Herndon, James E.

AU - Patz, Edward F.

PY - 2009/2/1

Y1 - 2009/2/1

N2 - BACKGROUND: In clinical trials, change in tumor size is used to stratify patients into response categories. The objective of the current study was to: 1) determine whether early change in the tumor size were correlated with survival in patients with advanced nonsmall cell lung cancer (NSCLC) using modified response categories from the Response Evaluation Criteria in Solid Tumors (RECIST), and 2) to determine whether there was an optimal percentage change in tumor size that could be used to define a partial response that also correlated with survival. METHODS: A total of 99 consecutive patients presenting for the treatment of advanced NSCLC during the year 2003 who had computed tomography (CT) scans before and after treatment available for review were included in the study. The largest target thoracic lesion was measured on CT before treatment, and again 2 months to 3 months after the initiation of treatment. Percent change in tumor size was calculated. The relation between tumor response and patient survival was investigated. RESULTS: There was no definite relation noted between early tumor response and patient survival (P = .754). Patients who had any initial reduction in tumor size were not found to have a significantly different survival compared with patients with initial disease progression (P = .580). In addition, there was no particular percent reduction in tumor size that was found to optimally correlate with survival. CONCLUSIONS: There is no evidence of a relation between early changes in tumor size and survival among patients with advanced stage NSCLC. To predict survival in patients with advanced NSCLC, response criteria other than change in lesion size are needed.

AB - BACKGROUND: In clinical trials, change in tumor size is used to stratify patients into response categories. The objective of the current study was to: 1) determine whether early change in the tumor size were correlated with survival in patients with advanced nonsmall cell lung cancer (NSCLC) using modified response categories from the Response Evaluation Criteria in Solid Tumors (RECIST), and 2) to determine whether there was an optimal percentage change in tumor size that could be used to define a partial response that also correlated with survival. METHODS: A total of 99 consecutive patients presenting for the treatment of advanced NSCLC during the year 2003 who had computed tomography (CT) scans before and after treatment available for review were included in the study. The largest target thoracic lesion was measured on CT before treatment, and again 2 months to 3 months after the initiation of treatment. Percent change in tumor size was calculated. The relation between tumor response and patient survival was investigated. RESULTS: There was no definite relation noted between early tumor response and patient survival (P = .754). Patients who had any initial reduction in tumor size were not found to have a significantly different survival compared with patients with initial disease progression (P = .580). In addition, there was no particular percent reduction in tumor size that was found to optimally correlate with survival. CONCLUSIONS: There is no evidence of a relation between early changes in tumor size and survival among patients with advanced stage NSCLC. To predict survival in patients with advanced NSCLC, response criteria other than change in lesion size are needed.

KW - Change in lesion size

KW - Computed tomography

KW - Nonsmall cell lung cancer

KW - RECIST

KW - Survival

KW - Tumor measurements

KW - Tumor response

UR - http://www.scopus.com/inward/record.url?scp=60049100489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60049100489&partnerID=8YFLogxK

U2 - 10.1002/cncr.24060

DO - 10.1002/cncr.24060

M3 - Article

C2 - 19117348

AN - SCOPUS:60049100489

VL - 115

SP - 581

EP - 586

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -